XPS™ sold to pediatric transplantation clinic in Italy

A pediatric transplantation clinic in Rome, Italy, has purchased an XPS™. This is the first XPS ™ for a pediatric hospital which will enable more transplants for children and adolescents with terminal lung disease.

There are approximately 200 lung transplants performed every year in Italy, whereof today only a few are pediatric lung transplants. The most common indication for lung transplantation in children is Cystic Fibrosis, a genetic disorder that causes thick mucus in the lungs. Clinics in Italy have been among the first to use EVLP to increase the proportion of lungs for transplantation to adults.

According to the Company’s business model, the pricing strategy for capital goods, that is the EVLP machines LS™ and XPS™, is so designed that sales of capital goods do not have a significant financial impact on the Company. According to the Company’s pricing strategy, future sales of STEEN Solution™ for use in the EVLP machines and accompanying single-use items are of financial significance for the Company.  

 “The EVLP technology, which allows more donated lungs to be used, has so far been used solely to evaluate lungs for transplantation to adults. The fact that the pediatric clinic in Rome is now the first in the world to buy an XPS ™ is very gratifying as it opens up to be able to expand the use of donated lungs for transplantation for children with terminal lung diseases.”, says Magnus Nilsson,

CEO of XVIVO Perfusion.

March 31, 2020
Magnus Nilsson, CEO

XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.  The information was submitted for publication, through the agency of the contact person set out above, at 09:30 am CET on March 31, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com



Documents & Links